12:00 AM
May 14, 2012
 |  BC Week In Review  |  Company News  |  Other News

Actelion pharmaceuticals news

At March 31, the company had CHF1.6 billion ($1.8 billion) in cash, including CHF365 million ($404.6 million) in restricted cash. Actelion had 2011 operating income of CHF12.2 million ($13.4 million). The company spent CHF457.7 million ($500.9 million) on R&D in 2011.

Read the full 186 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >